

# Hepatitis A - Market Insight, Epidemiology and Market Forecast - 2028

<https://marketpublishers.com/r/H38CBCC71F1EN.html>

Date: January 2019

Pages: 100

Price: US\$ 6,250.00 (Single User License)

ID: H38CBCC71F1EN

## Abstracts

This report can be delivered to the clients within 7-10 Business Days

DelveInsight's 'Hepatitis A - Market Insight, Epidemiology and Market Forecast - 2028' report provides a detailed analysis of the Hepatitis A epidemiology and market outlook for the 7MM.

## MARKETS COVERED

United States

EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Japan

Study Period: 2016-2028

Hepatitis A Understanding and Treatment Algorithm

The market report provides the overview of the Hepatitis A by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.

Hepatitis A Epidemiology

The report provides a comprehensive account of the total patient pool, diagnosed cases

and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2016 to 2028 segmented by seven major markets, enabling to understand the potential of the Hepatitis A in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

#### Hepatitis A Product Profiles & Analysis

The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.

#### Hepatitis A Market Outlook

The report's market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Hepatitis A market.

#### Hepatitis A Market Share by Therapies

This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2028. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.

#### Hepatitis A Report Insights

Patient Population in Hepatitis A

Therapeutic Approaches in Hepatitis A

Hepatitis A Pipeline Analysis

Hepatitis A Market Size and Trends

Hepatitis A Market Opportunities

Impact of upcoming Therapies in Hepatitis A

### Hepatitis A Report Key Strengths

10 Year Forecast

7MM Coverage

Epidemiology Segmentation

Drugs Uptake

Highly Analyzed Market

Key Cross Competition

### Hepatitis A Report Assessment

Current Treatment Practices in Hepatitis A

Unmet Needs in Hepatitis A

Market Attractiveness

Market Drivers and Barriers

### **KEY BENEFITS**

The report will help to develop Business Strategies by understanding the trends shaping and driving the Hepatitis A market

Organize sales and marketing efforts by identifying the best opportunities for Hepatitis A market

To understand the future market competition in the Hepatitis A market.

## Contents

### **1. REPORT INTRODUCTION**

### **2. HEPATITIS A MARKET OVERVIEW AT A GLANCE**

2.1. Market Share Distribution of Hepatitis A in 2016

2.2. Market Share Distribution of Hepatitis A in 2028

### **3. DISEASE BACKGROUND AND OVERVIEW: HEPATITIS A**

3.1. Introduction

3.2. Symptoms

3.3. Etiology

3.4. Risk Factors

3.5. Pathophysiology

3.6. Diagnosis

3.7. Treatment

### **4. EPIDEMIOLOGY AND PATIENT POPULATION**

4.1. Key Findings

4.2. Total Prevalent/ Incident Patient Population of Hepatitis A in 7MM

4.3. Total Prevalent Patient Population of Hepatitis A in 7MM – By Countries

### **5. EPIDEMIOLOGY OF HEPATITIS A BY COUNTRIES**

5.1. United States

5.1.1. Assumptions and Rationale

5.1.2. Prevalent/Incident Cases of the Hepatitis A

5.1.3. Sub-Type Specific cases of the Hepatitis A

5.1.4. Sex- Specific Cases of the Hepatitis A

5.1.5. Diagnosed Cases of the Hepatitis A

5.1.6. Treatable Cases of the Hepatitis A

5.2. EU5

5.3. Assumptions and Rationale

5.4. Germany

5.4.1. Assumptions and Rationale

5.4.2. Prevalent/Incident Cases of the Hepatitis A

- 5.4.3. Sub-Type Specific cases of the Hepatitis A
- 5.4.4. Sex- Specific Cases of the Hepatitis A
- 5.4.5. Diagnosed Cases of the Hepatitis A
- 5.4.6. Treatable Cases of the Hepatitis A
- 5.5. France
  - 5.5.1. Assumptions and Rationale
  - 5.5.2. Prevalent/Incident Cases of the Hepatitis A
  - 5.5.3. Sub-Type Specific cases of the Hepatitis A
  - 5.5.4. Sex- Specific Cases of the Hepatitis A
  - 5.5.5. Diagnosed Cases of the Hepatitis A
  - 5.5.6. Treatable Cases of the Hepatitis A
- 5.6. Italy
  - 5.6.1. Assumptions and Rationale
  - 5.6.2. Prevalent/Incident Cases of the Hepatitis A
  - 5.6.3. Sub-Type Specific cases of the Hepatitis A
  - 5.6.4. Sex- Specific Cases of the Hepatitis A
  - 5.6.5. Diagnosed Cases of the Hepatitis A
  - 5.6.6. Treatable Cases of the Hepatitis A
- 5.7. Spain
  - 5.7.1. Assumptions and Rationale
  - 5.7.2. Prevalent/Incident Cases of the Hepatitis A
  - 5.7.3. Sub-Type Specific cases of the Hepatitis A
  - 5.7.4. Sex- Specific Cases of the Hepatitis A
  - 5.7.5. Diagnosed Cases of the Hepatitis A
  - 5.7.6. Treatable Cases of the Hepatitis A
- 5.8. United Kingdom
  - 5.8.1. Assumptions and Rationale
  - 5.8.2. Prevalent/Incident Cases of the Hepatitis A
  - 5.8.3. Sub-Type Specific cases of the Hepatitis A
  - 5.8.4. Sex- Specific Cases of the Hepatitis A
  - 5.8.5. Diagnosed Cases of the Hepatitis A
  - 5.8.6. Treatable Cases of the Hepatitis A
- 5.9. Japan
  - 5.9.1. Assumptions and Rationale
  - 5.9.2. Prevalent/Incident Cases of the Hepatitis A
  - 5.9.3. Sub-Type Specific cases of the Hepatitis A
  - 5.9.4. Sex- Specific Cases of the Hepatitis A
  - 5.9.5. Diagnosed Cases of the Hepatitis A
  - 5.9.6. Treatable Cases of the Hepatitis A

## **6. CURRENT TREATMENT & MEDICAL PRACTICES**

- 6.1. Treatment Algorithm
- 6.2. Treatment Guidelines

## **7. UNMET NEEDS OF THE HEPATITIS A**

## **8. MARKETED THERAPIES**

- 8.1. Drug A: Company
  - 8.1.1. Drug Description
  - 8.1.2. Mechanism of Action
  - 8.1.3. Regulatory Milestones
  - 8.1.4. Advantages & Disadvantages
  - 8.1.5. Product Profile
- 8.2. Drug B: Company
  - 8.2.1. Drug Description
  - 8.2.2. Mechanism of Action
  - 8.2.3. Regulatory Milestones
  - 8.2.4. Advantages & Disadvantages
  - 8.2.5. Product Profile

## **9. PIPELINE THERAPIES – AT A GLANCE**

## **10. KEY CROSS COMPETITION**

## **11. EMERGING THERAPIES FOR HEPATITIS A**

- 11.1. Drug C: Company
  - 11.1.1. Drug Description
  - 11.1.2. Clinical Trials Details
  - 11.1.3. Safety and Efficacy Profile
  - 11.1.4. Advantages & Disadvantages
  - 11.1.5. Pipeline Development Activities
  - 11.1.6. Product Profile
- 11.2. Drug D: Company
  - 11.2.1. Drug Description
  - 11.2.2. Clinical Trials Details

- 11.2.3. Safety and Efficacy Profile
- 11.2.4. Advantages & Disadvantages
- 11.2.5. Pipeline Development Activities
- 11.2.6. Product Profile

## **12. HEPATITIS A: 7MM MARKET ANALYSIS**

- 12.1. 7MM Market Size of Hepatitis A
- 12.2. 7MM Percentage Share of drugs marketed for Hepatitis A
- 12.3. 7MM Market Sales of Hepatitis A by Products

## **13. HEPATITIS A: COUNTRY-WISE MARKET ANALYSIS**

- 13.1. United States
  - 13.1.1. Market Size of Hepatitis A in United States
  - 13.1.2. Percentage Share of drugs marketed for Hepatitis A in United States
  - 13.1.3. Market Sales of Hepatitis A by Products in United States
  - 13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
- 13.2. EU-5
  - 13.2.1. Germany
    - 13.2.1.1. Market Size of Hepatitis A in Germany
    - 13.2.1.2. Percentage Share of drugs marketed for Hepatitis A in Germany
    - 13.2.1.3. Market Sales of Hepatitis A by Products in Germany
    - 13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
  - 13.2.2. France
    - 13.2.2.1. Market Size of Hepatitis A in France
    - 13.2.2.2. Percentage Share of drugs marketed for Hepatitis A in France
    - 13.2.2.3. Market Sales of Hepatitis A by Products in France
    - 13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
  - 13.2.3. Italy
    - 13.2.3.1. Market Size of Hepatitis A in Italy
    - 13.2.3.2. Percentage Share of drugs marketed for Hepatitis A in Italy
    - 13.2.3.3. Market Sales of Hepatitis A by Products in Italy
    - 13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
  - 13.2.4. Spain
    - 13.2.4.1. Market Size of Hepatitis A in Spain
    - 13.2.4.2. Percentage Share of drugs marketed for Hepatitis A in Spain
    - 13.2.4.3. Market Sales of Hepatitis A by Products in Spain
    - 13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market



### 13.2.5. United Kingdom

13.2.5.1. Market Size of Hepatitis A in United Kingdom

13.2.5.2. Percentage Share of drugs marketed for Hepatitis A in United Kingdom

13.2.5.3. Market Sales of Hepatitis A by Products in United Kingdom

13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market

### 13.3. Japan

13.3.1. Market Size of Hepatitis A in Japan

13.3.2. Percentage Share of drugs marketed for Hepatitis A in Japan

13.3.3. Market Sales of Hepatitis A by Products in Japan

13.3.4. Analysis of Upcoming Therapies and their Impact on the Market

## **14. MARKET DRIVERS**

## **15. MARKET BARRIERS**

## **16. APPENDIX**

## **17. REPORT METHODOLOGY**

17.1. Sources

## **18. DELVEINSIGHT CAPABILITIES**

## **19. DISCLAIMER**

## **20. ABOUT DELVEINSIGHT**

Indication Specific

## List Of Tables

### LIST OF TABLES

- Table 1: Total Prevalent/Incident Cases of the Hepatitis A in 7MM
- Table 2: Total Prevalent/Incident Cases of the Hepatitis A in 7MM by Countries
- Table 3: Prevalent/Incident Cases of the Hepatitis A in United States (2016-2028)
- Table 4: Sub-Type Specific cases of the Hepatitis A in United States (2016-2028)
- Table 5: Sex- Specific Cases of the Hepatitis A in United States (2016-2028)
- Table 6: Diagnosed Cases of the Hepatitis A in United States (2016-2028)
- Table 7: Treatable Cases of the Hepatitis A in United States (2016-2028)
- Table 8: Prevalent/Incident Cases of the Hepatitis A in Germany (2016-2028)
- Table 9: Sub-Type Specific cases of the Hepatitis A in Germany (2016-2028)
- Table 10: Sex- Specific Cases of the Hepatitis A in Germany (2016-2028)
- Table 11: Diagnosed Cases of the Hepatitis A in Germany (2016-2028)
- Table 12: Treatable Cases of the Hepatitis A in Germany (2016-2028)
- Table 13: Prevalent/Incident Cases of the Hepatitis A in France (2016-2028)
- Table 14: Sub-Type Specific cases of the Hepatitis A in France (2016-2028)
- Table 15: Sex- Specific Cases of the Hepatitis A in France (2016-2028)
- Table 16: Diagnosed Cases of the Hepatitis A in France (2016-2028)
- Table 17: Treatable Cases of the Hepatitis A in France (2016-2028)
- Table 18: Prevalent/Incident Cases of the Hepatitis A in Italy (2016-2028)
- Table 19: Sub-Type Specific cases of the Hepatitis A in Italy (2016-2028)
- Table 20: Sex- Specific Cases of the Hepatitis A in Italy (2016-2028)
- Table 21: Diagnosed Cases of the Hepatitis A in Italy (2016-2028)
- Table 22: Treatable Cases of the Hepatitis A in Italy (2016-2028)
- Table 23: Prevalent/Incident Cases of the Hepatitis A in Spain (2016-2028)
- Table 24: Sub-Type Specific cases of the Hepatitis A in Spain (2016-2028)
- Table 25: Sex- Specific Cases of the Hepatitis A in Spain (2016-2028)
- Table 26: Diagnosed Cases of the Hepatitis A in Spain (2016-2028)
- Table 27: Treatable Cases of the Hepatitis A in Spain (2016-2028)
- Table 28: Prevalent/Incident Cases of the Hepatitis A in UK (2016-2028)
- Table 29: Sub-Type Specific cases of the Hepatitis A in UK (2016-2028)
- Table 30: Sex- Specific Cases of the Hepatitis A in UK (2016-2028)
- Table 31: Diagnosed Cases of the Hepatitis A in UK (2016-2028)
- Table 32: Treatable Cases of the Hepatitis A in UK (2016-2028)
- Table 33: Prevalent/Incident Cases of the Hepatitis A in Japan (2016-2028)
- Table 34: Sub-Type Specific cases of the Hepatitis A in Japan (2016-2028)
- Table 35: Sex- Specific Cases of the Hepatitis A in Japan (2016-2028)

- Table 36: Diagnosed Cases of the Hepatitis A in Japan (2016-2028)
- Table 37: Treatable Cases of the Hepatitis A in Japan (2016-2028)
- Table 38: Marketed Therapies
- Table 39: Emerging Therapies
- Table 40: Key Cross Competition
- Table 41:7MM- Market Size of Hepatitis A in USD MM (2016-2028)
- Table 42:7MM- Market Share Hepatitis A by Therapies in USD MM (2016-2028)
- Table 43:7MM- Market Sales of Hepatitis A by Therapies in USD MM (2016-2028)
- Table 44: United States-Market Size of Hepatitis A in USD MM (2016-2028)
- Table 45: United States-Market Share Hepatitis A by Therapies in USD MM (2016-2028)
- Table 46: United States-Market Sales of Hepatitis A by Therapies in USD MM (2016-2028)
- Table 47: Germany-Market Size of Hepatitis A in USD MM (2016-2028)
- Table 48: Germany-Market Share Hepatitis A by Therapies in USD MM (2016-2028)
- Table 49: Germany-Market Sales of Hepatitis A by Therapies in USD MM (2016-2028)
- Table 50: France-Market Size of Hepatitis A in USD MM (2016-2028)
- Table 51: France-Market Share Hepatitis A by Therapies in USD MM (2016-2028)
- Table 52: France-Market Sales of Hepatitis A by Therapies in USD MM (2016-2028)
- Table 53: Italy-Market Size of Hepatitis A in USD MM (2016-2028)
- Table 54: Italy-Market Share Hepatitis A by Therapies in USD MM (2016-2028)
- Table 55: Italy-Market Sales of Hepatitis A by Therapies in USD MM (2016-2028)
- Table 56: Spain-Market Size of Hepatitis A in USD MM (2016-2028)
- Table 57: Spain-Market Share Hepatitis A by Therapies in USD MM (2016-2028)
- Table 58: Spain-Market Sales of Hepatitis A by Therapies in USD MM (2016-2028)
- Table 59:UK-Market Size of Hepatitis A in USD MM (2016-2028)
- Table 60:UK-Market Share Hepatitis A by Therapies in USD MM (2016-2028)
- Table 61:UK-Market Sales of Hepatitis A by Therapies in USD MM (2016-2028)
- Table 62: Japan-Market Size of Hepatitis A in USD MM (2016-2028)
- Table 63: Japan-Market Share Hepatitis A by Therapies in USD MM (2016-2028)
- Table 64: Japan-Market Sales of Hepatitis A by Therapies in USD MM (2016-2028)

## List Of Figures

### LIST OF FIGURES

- Figure 1: Total Prevalent/Incident Cases of the Hepatitis A in 7MM
- Figure 2: Total Prevalent/Incident Cases of the Hepatitis A in 7MM by Countries
- Figure 3: Prevalent/Incident Cases of the Hepatitis A in United States (2016-2028)
- Figure 4: Sub-Type Specific cases of the Hepatitis A in United States (2016-2028)
- Figure 5: Sex- Specific Cases of the Hepatitis A in United States (2016-2028)
- Figure 6: Diagnosed Cases of the Hepatitis A in United States (2016-2028)
- Figure 7: Treatable Cases of the Hepatitis A in United States (2016-2028)
- Figure 8: Prevalent/Incident Cases of the Hepatitis A in Germany (2016-2028)
- Figure 9: Sub-Type Specific cases of the Hepatitis A in Germany (2016-2028)
- Figure 10: Sex- Specific Cases of the Hepatitis A in Germany (2016-2028)
- Figure 11: Diagnosed Cases of the Hepatitis A in Germany (2016-2028)
- Figure 12: Treatable Cases of the Hepatitis A in Germany (2016-2028)
- Figure 13: Prevalent/Incident Cases of the Hepatitis A in France (2016-2028)
- Figure 14: Sub-Type Specific cases of the Hepatitis A in France (2016-2028)
- Figure 15: Sex- Specific Cases of the Hepatitis A in France (2016-2028)
- Figure 16: Diagnosed Cases of the Hepatitis A in France (2016-2028)
- Figure 17: Treatable Cases of the Hepatitis A in France (2016-2028)
- Figure 18: Prevalent/Incident Cases of the Hepatitis A in Italy (2016-2028)
- Figure 19: Sub-Type Specific cases of the Hepatitis A in Italy (2016-2028)
- Figure 20: Sex- Specific Cases of the Hepatitis A in Italy (2016-2028)
- Figure 21: Diagnosed Cases of the Hepatitis A in Italy (2016-2028)
- Figure 22: Treatable Cases of the Hepatitis A in Italy (2016-2028)
- Figure 23: Prevalent/Incident Cases of the Hepatitis A in Spain (2016-2028)
- Figure 24: Sub-Type Specific cases of the Hepatitis A in Spain (2016-2028)
- Figure 25: Sex- Specific Cases of the Hepatitis A in Spain (2016-2028)
- Figure 26: Diagnosed Cases of the Hepatitis A in Spain (2016-2028)
- Figure 27: Treatable Cases of the Hepatitis A in Spain (2016-2028)
- Figure 28: Prevalent/Incident Cases of the Hepatitis A in UK (2016-2028)
- Figure 29: Sub-Type Specific cases of the Hepatitis A in UK (2016-2028)
- Figure 30: Sex- Specific Cases of the Hepatitis A in UK (2016-2028)
- Figure 31: Diagnosed Cases of the Hepatitis A in UK (2016-2028)
- Figure 32: Treatable Cases of the Hepatitis A in UK (2016-2028)
- Figure 33: Prevalent/Incident Cases of the Hepatitis A in Japan (2016-2028)
- Figure 34: Sub-Type Specific cases of the Hepatitis A in Japan (2016-2028)
- Figure 35: Sex- Specific Cases of the Hepatitis A in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Hepatitis A in Japan (2016-2028)

Figure 37: Treatable Cases of the Hepatitis A in Japan (2016-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Hepatitis A in USD MM (2016-2028)

Figure 42:7MM- Market Share Hepatitis A by Therapies in USD MM (2016-2028)

Figure 43:7MM- Market Sales of Hepatitis A by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Hepatitis A in USD MM (2016-2028)

Figure 45: United States-Market Share Hepatitis A by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Hepatitis A by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Hepatitis A in USD MM (2016-2028)

Figure 48: Germany-Market Share Hepatitis A by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Hepatitis A by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Hepatitis A in USD MM (2016-2028)

Figure 51: France-Market Share Hepatitis A by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Hepatitis A by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Hepatitis A in USD MM (2016-2028)

Figure 54: Italy-Market Share Hepatitis A by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Hepatitis A by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Hepatitis A in USD MM (2016-2028)

Figure 57: Spain-Market Share Hepatitis A by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Hepatitis A by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Hepatitis A in USD MM (2016-2028)

Figure 60:UK-Market Share Hepatitis A by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Hepatitis A by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Hepatitis A in USD MM (2016-2028)

Figure 63: Japan-Market Share Hepatitis A by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Hepatitis A by Therapies in USD MM (2016-2028)

## I would like to order

Product name: Hepatitis A - Market Insight, Epidemiology and Market Forecast - 2028

Product link: <https://marketpublishers.com/r/H38CBCC71F1EN.html>

Price: US\$ 6,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H38CBCC71F1EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970